ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's event where we have the pleasure to present Expression Biotech. To help us through today's presentation we are joined by CEO Ben Fransen and CFO Keith Alexander. The topic for today of course the Q2 results fresh from the press this morning but maybe also more the strong data which I That's how you have communicated during the course on your breast cancer candidate. So that will be the main topics for today's presentation. As always, there's a box down below where you can ask questions. Do feel free to do it during the presentation, but we will take the Q&A in the end. And for informal, we have a fixed deadline at 10.30, so we will try and catch all the questions. But if not, then of course they are free to send it to you. But that was all the messaging before that. So now I will hand the stage over to you, Ben. Thank you very much, Michael. And good morning, everybody. And welcome to Expressions Q2 2026 Results Webcast. I'm Ben Fransen, CEO, and I'm joined today by our CFO, Kate Kees and Alexander. I will begin with our operational. to focus on ES2B C001. This will then take us through the Q&A to refer to our financial results, from which we will open for questions. Our agenda is straightforward. First, key updates on the corner, and second, our financial results, final Q&A. A short-looking statement disclaimer in the presentation, which we'll publish on our web page afterwards, after this webinar. Since our last quarterly update, we have advanced our clinical program, our platform, and our financing activities. During Q2, we published a patent application in Hong Kong, strengthening our glycoengineering platform, highlighted clinical malaria data supporting platform validation and scalability, and completed the rights issue and provided a further...